HUTCHMED, formerly known as Hutchison China MediTech Limited (HCM), is an innovative biopharmaceutical company that is working tirelessly to transform the future of healthcare. Core to their mission is the development, manufacture, and sale of highly advanced biopharmaceutical products that target critical ailments. The company aims to deliver groundbreaking and life-saving therapeutic treatments in oncology and immunological diseases that will impact patients worldwide.
HUTCHMED is focused on the global development and commercialization of targeted therapeutics and immunotherapies. The company has developed a broad and diverse pipeline of research and development programs around novel oral small molecules and monoclonal antibodies for the treatment of cancer and immunological diseases, bolstering their capability to combat some of the most persistent healthcare challenges.
Founded in 2000 and based in Hong Kong and Shanghai, the company has sought to capitalize on the extensive scientific and medical research capabilities in China. It has built a world-class platform that is fully integrated, from discovery and development to manufacturing and global commercialization. By investing in the Chinese biopharmaceutical sector, HUTCHMED aims to play a significant role in the advancement of global healthcare.
HUTCHMED is dedicated to creating a robust infrastructure that follows international best practices for pharmaceutical development and adopts state-of-the-art manufacturing facilities that comply with international GMP standards. It collaborates with several prestigious multinational pharmaceutical and biotechnology companies, expanding its market reach and accessibility to cutting-edge research and technology.
The company has a dynamic and experienced management team with an international perspective, bringing decades of experience in the pharmaceutical and biotechnology industries. HUTCHMED's team is committed to innovation, working diligently towards achieving the company's vision by continuously driving breakthrough advances in medicine.
HUTCHMED showcases its commitment to its mission consistently through its extensive product pipeline. Notable products include surufatinib, a novel oral drug for neuroendocrine tumors and biliary tract cancer, and savolitinib, a selective inhibitor being studied in multiple tumor types. These and many more innovative products in HUTCHMED's pipeline signify the company's development prowess and its potential to make significant inroads in disease treatment worldwide.
In 2021, HUTCHMED successfully listed on the Hong Kong Stock Exchange, the US NASDAQ, and the London Stock Exchange, facilitating its global aims for extensive and broad-reaching distribution of its pharmaceutical developments. This move also demonstrates the recognition and trust the global investment community has in HUTCHMED's scientific capabilities and its potential to create exceptional shareholder value.
HUTCHMED believes that by pioneering novel cancer and immunological disease treatment options, they can contribute significantly to global healthcare, providing life-changing benefits to patients across the world.